Drugs / allo-APZ2-CVU
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03257098 | Nov 2017 → Jun 2020 | chronic ulcer of skin | RHEACELL GmbH & Co. KG | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04971161 | Aug 2021 → Nov 2025 | chronic ulcer of skin | RHEACELL GmbH & Co. KG | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06489028 | Dec 2024 → Apr 2027 expected | ulcer of lower limbs | RHEACELL GmbH & Co. KG | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allo-APZ2-CVU | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04971161 ↗ |
| Modality | Cell therapy | “The allogeneic IMP allo-APZ2-CVU contains skin-derived ABCB5-positive dermal mesenchymal stromal cells isolated from skin tissue of healthy donors and stored in a donor cell bank.” NCT06489028 ↗ |
| Route | Topical | “The IMP incorporating the ABCB5-positive MSCs will then be applied on the wound surface of CVU” NCT03257098 ↗ |